Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders' Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL).

ABSTRACT:

Background

Healthcare decision makers need to make trade-offs between different elements of value of new treatments. Multicriteria decision analysis (MCDA) provides a framework that can help decision makers to understand stakeholders' preferences and be explicit about the trade-offs that are being made.

Objective

The objective of this study was to use MCDA to obtain preferences and views on decision criteria across three stakeholder groups (patients, clinicians and payers) in Italy and to use these to assess the performance of obinutuzumab for rituximab-refractory indolent non-Hodgkin lymphoma (iNHL).

Methods

We used EVIDEM V3.0, an MCDA framework, and collected participants' preferences via an online survey and structured meetings.

Results

Patients and clinici

SUBMITTER: Garau M 

PROVIDER: S-EPMC5972119 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature